| Description | Casp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Casp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control. Components Casp3 siRNA-1: 5 nmol (HPLC) Casp3 siRNA-2: 5 nmol (HPLC) Casp3 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 Casp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Casp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control. Components Casp3 siRNA-1: 5 nmol (HPLC) Casp3 siRNA-2: 5 nmol (HPLC) Casp3 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description: This protein is a cell adhesion molecule involved in neuron-neuron adhesion, neurite fasciculation, outgrowth of neurites, etc | Purity>95% (SDS-PAGE) Endotoxin level<1.0 EU/µgFunctionInhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells | Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases... Read More |